Michael D Karlstad

US Patent:

56611803, Aug 26, 1997

Filed:

Mar 30, 1995

Appl. No.:

8/410581

Inventors:

Stephen Joseph DeMichele - Dublin OH
Michael Donald Karlstad - Knoxville TN
Bruce Ryan Bistrian - Ipswich MA
Edward Anthony Mascioli - Needham MA

Assignee:

Abbott Laboratories - Abbott Park IL
New England Deaconess Hospital - Boston MA
University of Tennessee Research Corporation - Knoxville TN

International Classification:

A61K 3120

US Classification:

514547

Abstract:

There is disclosed structured lipid containing either a gamma-linolenic acid or a dihomogamma-linolenic acid residue, together with an n-3 fatty acid residue and a medium chain fatty acid residue on the same glycerol backbone. This structured lipid is particularly well adapted to the treatment of disease or stress states. The gamma-linolenic or dihomogamma-linolenic acid residues modify the prostanoid synthesis pathway, reducing the level of series "2" prostanoids and elevating the levels of series "1" and "3" prostanoids. The n-3 fatty acid residue enhances the level of series "1" prostanoids as well as increases the production of series "3" prostanoids. The medium chain fatty acid residues enhances the absorption of the structured lipid. There is also disclosed enteral and parenteral diets as well as nutritional supplements containing the structured lipids of the invention.

US Patent:

59627123, Oct 5, 1999

Filed:

Apr 23, 1997

Appl. No.:

8/839086

Inventors:

Stephen Joseph DeMichele - Dublin OH
Michael Donald Karlstad - Knoxville TN
Bruce Ryan Bistrian - Ipswich MA
Edward Anthony Mascioli - Needham MA

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

C07C 5300

US Classification:

554224

Abstract:

There is disclosed structured lipid containing either a gamma-linolenic acid or a dihomogamma-linolenic acid residue, together with an n-3 fatty acid residue and a medium chain fatty acid residue on the same glycerol backbone. This structured lipid is particularly well adapted to the treatment of disease or stress states. The gamma-linolenic or dihomogamma-linolenic acid residues modify the prostanoid synthesis pathway, reducing the level of series "2" prostanoids and elevating the levels of series "1" and "3" prostanoids. The n-3 fatty acid residue enhances the level of series "1" prostanoids as well as increases the production of series "3" prostanoids. The medium chain fatty acid residues enhances the absorption of the structured lipid. There is also disclosed enteral and parenteral diets as well as nutritional supplements containing the structured lipids of the invention.